Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 88

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 88
---
 333-251857). Such warrants and placement agent warrants are referred to herein as the “Outstanding Registered Warrants”. DESCRIPTION OF UNITS We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The applicable prospectus supplement will describe:

| • | the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |

| • | the material terms of a unit agreement under which the units will be issued; |

| • | any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities comprising the units; and |

| • | whether the units will be issued in fully registered or global form. |

The applicable prospectus supplement will describe the terms of any units. The preceding description and any description of units in the applicable prospectus supplement does not purport to be complete and is subject to and is qualified in its entirety by reference to the unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. For more information on how you can obtain copies of the applicable unit agreement if we offer units, see “Where You Can Find More Information” beginning on page 40 and “Incorporation of Certain Documents by Reference” beginning on page 41. We urge you to read the applicable unit agreement and any applicable prospectus supplement in their entirety. 33 TAXATION The material Israeli and U.S. federal income tax consequences relating to the purchase, ownership, and disposition of any of the securities offered by this prospectus will be set forth in the prospectus supplement offering those securities or incorporated by reference from our Annual Report on Form 20-F or other public filings we make with the SEC. 34 PLAN OF DISTRIBUTION The securities being offered by this prospectus may be sold:

| ● | through agents; |

| ● | to or through one or more underwriters on a firm commitment or agency basis; |

| ● | through put or call option transactions relating to the securities; |

| ● | to or